ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

Consensus Conference agrees That Nevi Can Be Precursors For Melanoma, Offers Management Suggestions

November 4, 1983

ORI takes Over Misconduct Inquiry Of NSABP Officials

July 29, 1994

Biopsies Could Be Reduced By Computer-Aided-Detection

December 26, 2003

Massive Opposition Building To OMB Cuts; Legislative, Court Actions Predicted

February 22, 1985

In Brief: Kenneth Olden Named Director Of Howard Cancer Center; Calhoon Sparked AMA On Cigarette Ads

February 21, 1986

Special Issue: Broder Resigns NCI To Take Job With Drug Company IVAX

December 22, 1994